Koru Medical reports preliminary Q4 revenue $10.9M, consensus $10.46M

Reports preliminary FY25 revenue $41.1M, consensus $40.69M. “We delivered strong fourth quarter results and enter 2026 with solid momentum, driven by continued strength in our core immunoglobulin business and growth in our recurring patient base,” said Linda Tharby, President and CEO of Koru Medical (KRMD). “Our international expansion strategy is on track, and our recent 510(k) submission for clearance of the Freedom Infusion System for use with Phesgo(R) represents a key milestone in expanding beyond Ig into oncology. With continued disciplined execution on all aspects of our strategy, we are positioned well for sustainable growth in 2026 and beyond.”